TXG’s Q2 2026 Playbook: Margin Up, Net Loss Persists, and the 2026 Revenue Forecast Shifts Higher

Overview: A Quarter of Contrasts

10x Genomics reported second-quarter 2026 results with revenue of $151.0 million, down from $172.9 million in the prior-year period. The variance is largely attributable to a non-recurring patent-settlement tailwind that is absent in the latest quarter; excluding $1.6 million related to that settlement, revenue rose about 3% versus the 2025 comparable period.

Gross margin expanded to 74% from 72% in the year-ago quarter, driven by lower manufacturing costs and tariff refunds (about $2.6 million), offset by a shift in revenue mix and a reduction in non-recurring license and royalty revenue. Operating expenses rose to $132.1 million, a 39% year-over-year increase largely tied to the disappearance of a large prior-year gain on settlements; excluding settlements, costs were roughly flat.

Net loss for the quarter was $17.9 million, compared with net income of $34.5 million in the second quarter of 2025. On an ongoing basis, the quarter’s earnings dynamics translate into an EPS outcome that will depend on shares outstanding and non-GAAP considerations, which the release does not publish.

Guidance: A Raised Revenue Forecast and the Settlement Headwind

10x Genomics updated its full-year 2026 revenue guidance to a range of $610 million to $630 million, up from the prior range of $600 million to $625 million. The company characterizes the improvement as 2% to 5% growth over full-year 2025, excluding non-recurring license and royalty revenue related to patent settlements.

This framing suggests management is positioning the top line to outpace 2025 after stripping out the one-off settlement revenues that inflated the prior period. It’s a reminder that a segment of the growth narrative in biotech tooling often hinges as much on settlement timing and licensing dynamics as on underlying product adoption.

Strategic Moves and Momentum Catalysts

In the quarter, 10x Genomics underscored its multiomics push by noting the acquisition of Proteintech Genomics, a move that broadens its protein-detection capabilities within single-cell and spatial platforms. Management argues this enhances the company’s multiomics strategy and broadens the addressable market for diagnostics and research workflows.

The company also highlighted multi-year research collaborations with the Cleveland Clinic and Lausanne University Hospital aimed at advancing diagnostic applications of single-cell and spatial technologies for cancer care. These partnerships serve a dual purpose: elevating the science narrative and potentially expanding adoption through high-profile institutional endorsements.

On the leadership call, CEO Serge Saxonov highlighted robust early order flow and strong customer engagement around Atera, the company’s flagship platform narrative. The sentiment aligns with a sectorwide emphasis on platform-level value—where fewer SKUs and deeper integration can drive stickiness even as quarterly noise persists.

Analysis: What This Might Portend for TXG and the Sector

The Q2 results present a classic “margin discipline meets revenue cadence” narrative. The gross margin expansion suggests production efficiencies and tariff refunds are providing some insulation against cost pressures, even as operating expenses rose due to the absence of prior-year settlement gains. For investors, the key question becomes whether the revenue forecast uplift can translate into a sustainable path to profitability, especially if patent settlements normalize or fluctuate in the future.

The absence of a stated EPS consensus or a concrete EPS figure in the release creates a valuation crosswinds moment. If sell-side expectations anticipate a positive EPS, the reported net loss could be interpreted as a near-term earnings disappointment; if analysts are modeling minimal EPS impact due to one-time items, sentiment could skew the other way. Either way, the optionality around non-recurring items underscores the sensitivity of EPS to settlements, licensing arrangements, and share count.

From a sector perspective, TXG’s strategy—protein genomics expansion, strategic collaborations, and a push into multiomics—signals continued investor interest in players that can monetize a combined biology-and-technology stack. Peers focusing on single-cell and spatial platforms may monitor whether TXG’s blended approach to product, services, and partnerships translates into durable competitive advantages or simply a temporary edge before the next settlement or licensing cycle.

In the near term, the stock’s trajectory may hinge on how convincingly TXG can translate a raised revenue forecast into sustained margin expansion and a path to floor-to-ceiling profitability. The elevated gross margin supports a constructive narrative, but investors will likely scrutinize cash generation, how much of the 2026 guidance hinges on non-recurring items, and whether the company can sustain top-line growth without repeating the post-period settlement dynamics.

Webcast, Call Information, and What to Listen For

10x Genomics will host a conference call to discuss the second-quarter 2026 results after market close on Thursday, August 6, 2026 at 1:30 PM Pacific Time / 4:30 PM Eastern Time. A webcast will be available, with an archived replay accessible for at least 45 days.

For investors tracking the revenue forecast and any potential earnings surprise, the webcast should illuminate management’s framing of non-recurring items, the trajectory of Atera’s adoption, and how Proteintech Genomics contributes to the broader pipeline.